Boylan James P 4

What Happened
James P. Boylan, a director of Zenas BioPharma (ZBIO), received a derivative award on 2026-06-15: an option covering 18,500 shares (transaction code A). The grant shows a $0.00 cash price on the Form 4 (no cash paid at grant); this is an equity award rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-15; Form 4 filed: 2026-06-17 (timely filing).
• Instrument: Derivative grant/award (option) for 18,500 shares; reported price $0.00.
• Vesting: 100% of the underlying shares vest on June 15, 2027, subject to continued service (Footnote F1).
• Beneficial ownership: The option is held for the benefit of Enavate Sciences, L.P.; Boylan disclaims beneficial ownership except for any pecuniary interest (Footnote F2).
• Shares owned after transaction: Not specified in the provided excerpt.

Context
This filing records an option grant (an award), not an immediate purchase or sale of stock. Such grants are typically part of compensation or director awards; they do not represent realized proceeds until exercised or sold. Because the option vests in one year, there is no current transfer of marketable shares.